Survival Machine Learning Methods Improve Prediction of Histologic Transformation in Follicular and Marginal Zone
Tong-Yoon Kim1,2, Tae-Jung Kim3, Eun Ji Han4
1Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea.
Cancers
|September 27, 2025
Summary
Machine learning models accurately predict histologic transformation risk in follicular lymphoma and marginal zone lymphoma. Integrating next-generation sequencing data further enhances prediction accuracy for these indolent B-cell lymphomas.
Area of Science:
- Hematology
- Oncology
- Computational Biology
Background:
- Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent B-cell lymphomas with a risk of transformation to aggressive subtypes.
- Predicting histologic transformation (HT) is challenging due to data complexities and class imbalances.
- Existing prognostic indices do not specifically target HT risk.
Purpose of the Study:
- Develop and validate machine learning models for predicting HT in FL and MZL.
- Compare the performance of survival-based and traditional classification models.
- Investigate the impact of next-generation sequencing (NGS) data on HT prediction.
Main Methods:
- Utilized a multicenter retrospective dataset (n=1068) for model development.
- Compared various survival models (e.g., XGBoost-Cox, Lasso-Cox) and classification models (e.g., Logistic Regression, Random Forest).
- Validated best-performing models on an independent test set (n=92) and incorporated NGS data.
Main Results:
- Survival models outperformed traditional classifiers in predicting HT.
- XGBoost-Cox demonstrated the highest predictive performance (accuracy 85.3%, AUC 0.795).
- NGS data integration improved model accuracy and specificity, identifying key genes like TP53, BLM, and RAD50 associated with HT risk.
Conclusions:
- Survival-based machine learning models offer significant clinical value for HT risk stratification.
- Integration with NGS data enables personalized risk assessment for FL and MZL patients.
- This approach can aid in clinical decision-making for managing these lymphomas.


